Tagrisso (osimertinib) has received Breakthrough Therapy Designation from FDA for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
Piqray (alpelisib) received approval from the European Commission in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.
The FDA's Oncology Center of Excellence and Syapse presented data at the American Association of Clinical Research COVID-19 and Cancer meeting on an analysis of more than 212,000 health records of people living with cancer across two major health systems in the Midwestern United States.
An updated cervical cancer screening guideline from the American Cancer Society reflects the rapidly changing landscape of cervical cancer prevention in the United States, calling for less and more simplified screening.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center are conducting a clinical trial to determine if ibrutinib (Imbruvica) can help patients with cancer or other immunocompromised conditions recover from COVID-19.
Researchers at Fox Chase Cancer Center found that older patients who underwent chemoradiation therapy followed by removal of their esophagus due to cancer had toxicities and outcomes similar to younger patients.
A study by UPMC and University of Pittsburgh School of Medicine researchers demonstrates the highest accuracy to date in recognizing and characterizing prostate cancer using an artificial intelligence program.
Oncology practices face difficult challenges while delivering care in the middle of COVID-19, as they care for patients who are at higher risk for this potentially deadly disease. While there is still much to learn about how COVID-19 impacts various patient populations, early studies of COVID-19 patients with a history of cancer provide some insight.
Winship Cancer Institute of Emory University received $7.8 million from the Paula and Rodger Riney Foundation to fund the Riney Family Multiple Myeloma Research Program Fund.
Ge Jin and Bingcheng Wang received a $3.7 million five-year grant to explore why those living with HIV have a higher risk for certain kinds of cancers, such as lung cancer.
